⏳ Fetching live dividend data...
Home › Calculator › CRSP Dividend Calculator 2026
CRISPR Therapeutics AG · NASDAQ
Price: $50.36 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in CRSP → $10.65M in 10 years · $34.42/month
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CRSP position with:
Real after-tax yield depends on where you live and how you hold CRSP.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.97% | 1.17% | $397 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.37% | 0.57% | $337 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.18% | 0.38% | $318 / yr |
| 🇬🇧 UK ISA | 0% | 3.97% | 1.17% | $397 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.62% | 0.82% | $362 / yr |
| 🇨🇦 TFSA | 0% | 3.97% | 1.17% | $397 / yr |
| 🇨🇦 CA Taxable | 25% | 2.98% | 0.18% | $298 / yr |
| 🇦🇺 Super (pension) | 15% | 3.37% | 0.57% | $337 / yr |
| 🇦🇺 AU Taxable | 30% | 2.78% | -0.02% | $278 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.92% | 0.12% | $292 / yr |
| 🇫🇷 FR Taxable | 30% | 2.78% | -0.02% | $278 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CRSP pays quarterly — 4 times per year. Next ex-div: TBD.
How CRSP compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CRSP sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K | ||
| A-Award | 2026-06-05 | 13,000 | $51.84 | $673.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CRSP dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →